Human Papilloma Virus Related Head and Neck Squamous Cell Carcinoma-an updated review

Jaspreet  Kaur

doi:10.52229/pbmj.v1i1.37

Authors

Jaspreet Kaur Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark

DOI:

https://doi.org/10.52229/pbmj.v1i1.37

Abstract

Human papilloma virus (HPV) related head and neck squamous cell cancer (HNSCC) has varying etiology, genetic as well as environmental factors involved and differential clinicicopathological features. HNSCC came in the limelight recently due to increased incidence rate and insufficient diagnostic methods. This review will comprehensively focus on the characteristics of HPV associated HNSCC. It will provide an updated review of our understanding of HPV role in Oral squamous cell carcinoma (OSCC) known to date. Curruntly, three vaccines are available (Gardasil, Gardasil 9 and Cervarix). These vaccines prevent infections with HPV types 16 and 18 HPV-16 is most common type associated with HNSCC. HPV related HNSCC has better prognosis, does not mutate but inactivatestumor suppressor genes and therefore has comparatively better treatment options. However, there is still a need to improve our methods of sampling, HPV molecular assay and type of specimen to be used.

References

De Sanjosé S, Serrano B, Castellsagué X, Brotons M, Muñoz J, Bruni L, et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012;30:D1-83.

Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: A growing global problem. International Journal of Applied and Basic Medical Research 2016;6:84.

De Villiers EM, Weidauer H, Otto H, Zur Hausen H. Papillomavirus DNA in human tongue carcinomas. International journal of cancer 1985;36:575-8.

Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Seminars in oncology: Elsevier; 2004. p. 744-54.

Humans IWGotEoCRt. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer 1995;64:1.

Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Muzio LL, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007). Annals of Oncology 2008:mdn372.

Dahlgren L, Dahlstrand HM, Lindquist D, Högmo A, Björnestål L, Lindholm J, et al. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. International journal of cancer 2004;112:1015-9.

Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clinical cancer research 2002;8:3187-92.

Bhargava A, Shakeel M, Srivastava A, Raza TS, Rizvi S, Varshney P. Role of human papilloma virus in oral leukoplakia. Indian journal of cancer 2016;53:206.

Sidransky D. Molecular genetics of head and neck cancer. Current opinion in oncology 1995;7:229-33.

D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine 2007;356:1944-56.

Rintala M, Grénman S, Puranen M, Syrjänen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. Journal of clinical virology 2006;35:89-94.

Ljubojevic S, Skerlev M. HPV-associated diseases. Clinics in dermatology 2014;32:227-34.

Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. Journal of Clinical Oncology 2006;24:736-47.

Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119:2620-3.

Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. The New England journal of medicine 2001;344:1125-31.

Bisht M, Bist SS. Human papilloma virus: a new risk factor in a subset of head and neck cancers. 2012.

Lawton G, Thomas S, Schonrock J, Monsour F, Frazer I. Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. Journal of oral pathology & medicine 1992;21:265-9.

Heath EM, Morken NW, Campbell KA, Tkach D, Boyd EA, Strom DA. Use of buccal cells collected in mouthwash as a source of DNA for clinical testing. Archives of pathology & laboratory medicine 2001;125:127-33.

Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Critical Reviews in Oral Biology & Medicine 2004;15:188-96.

Perrone F, Gloghini A, Cortelazzi B, Bossi P, Licitra L, Pilotti S. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. The American journal of surgical pathology 2011;35:774-7.

McNeil C. HPV in oropharyngeal cancers: new data inspire hope for vaccines. Journal of the National Cancer Institute 2000;92:680-1.

Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953;6:963-8.

Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. Cancer 2001;92:805-13.

Borysiewicz L, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 1996;347:1523-7.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007;356:1928-43.

Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007; 298(7):743–753.

Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Suppl 5:F123-138.